Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, . . . Federico Mensa. (2017). P49 MAGELLAN-1, PART 2: Glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Elsevier.
Chicago Style (17th ed.) CitationFred Poordad, et al. P49 MAGELLAN-1, PART 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure. Elsevier, 2017.
MLA (9th ed.) CitationFred Poordad, et al. P49 MAGELLAN-1, PART 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure. Elsevier, 2017.
Warning: These citations may not always be 100% accurate.